AnaptysBio Inc - Asset Resilience Ratio
AnaptysBio Inc (ANAB) has an Asset Resilience Ratio of 11.52% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of AnaptysBio Inc to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how AnaptysBio Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of AnaptysBio Inc.
Liquid Assets Composition Over Time
This chart breaks down AnaptysBio Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore AnaptysBio Inc long-term investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $37.99 Million | 11.52% |
| Total Liquid Assets | $37.99 Million | 11.52% |
Asset Resilience Insights
- Moderate Liquidity: AnaptysBio Inc has 11.52% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
AnaptysBio Inc Industry Peers by Asset Resilience Ratio
Compare AnaptysBio Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for AnaptysBio Inc (2017–2025)
The table below shows the annual Asset Resilience Ratio data for AnaptysBio Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 20.15% | $73.44 Million | $364.39 Million | -34.06pp |
| 2024-12-31 | 54.21% | $262.29 Million | $483.83 Million | -24.25pp |
| 2023-12-31 | 78.46% | $354.94 Million | $452.39 Million | +17.85pp |
| 2022-12-31 | 60.61% | $369.93 Million | $610.38 Million | +52.46pp |
| 2021-12-31 | 8.14% | $52.37 Million | $643.07 Million | -26.23pp |
| 2020-12-31 | 34.38% | $143.20 Million | $416.55 Million | -12.32pp |
| 2019-12-31 | 46.69% | $203.21 Million | $435.20 Million | -14.90pp |
| 2018-12-31 | 61.59% | $313.49 Million | $509.00 Million | +10.82pp |
| 2017-12-31 | 50.77% | $167.22 Million | $329.36 Million | -- |
About AnaptysBio Inc
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial… Read more